Is Bradykinin legal in Australia?

A 9 amino acid inflammatory mediator, not a therapy. It is the reason ACE inhibitors cause cough and angioedema, and human forearm and nerve studies have measured what it does; there is no clinical use for administering it.

Bradykinin is a 9 amino acid peptide, sequence RPPGFSPFR, released from kininogen by kallikrein enzymes during inflammation and tissue injury. It dilates blood vessels, increases vascular permeability and sensitises pain-carrying nerves.

Mechanism: In humans, bradykinin acts at two G protein-coupled receptors: B2, which is present constitutively, and B1, which is induced by inflammation. B2 activation on endothelium releases nitric oxide and prostacyclin, producing vasodilation and increased permeability; on nociceptors it lowers the threshold for firing.

Regulatory history: Not an approved drug. Bradykinin is an endogenous mediator and a laboratory reagent; no bradykinin product appeared in the Drugs@FDA checks run for this batch. The approved medicine acting on this system is the B2 receptor antagonist icatibant.

Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.

The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for Bradykinin at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.